For the Inventor, By the Inventor

Enter assignee name

Lexington, MA, United States of America

Synta Pharmaceuticals Corporation

USPTO Granted Patents = 162

CIPO Patents = 3

EPO Patents = 25

Trademarks = 2

Forward Citations = 1,723

Loading Chart...

Loading Chart...

71 inventors (with patents filed for the assignee):

Lijun Sun (100 out of 140 patents)

Shoujun Chen (66 out of 71 patents)

Weiwen Ying (54 out of 63 patents)

4. Keizo Koya (49 out of 58 patents)

5. Mitsunori Ono (38 out of 94 patents)

6. Dinesh U Chimmanamada (36 out of 46 patents)

7. Shijie Zhang (35 out of 39 patents)

8. Kevin Paul Foley (32 out of 32 patents)

9. Zhenjian Du (30 out of 30 patents)

10. Teresa Przewloka (30 out of 35 patents)

11. Jun Jiang (29 out of 32 patents)

12. Elena Kostik (28 out of 28 patents)

13. Zachary Demko (25 out of 80 patents)

14. Hao Li (24 out of 24 patents)

15. David James (24 out of 30 patents)

Core Competencies:

HSP90 Inhibitors

Combination Therapy

Cancer Treatment

Triazole Compounds

Inflammation Modulation

Proliferative Disorders

Targeted Therapeutics

EGFR Inhibitors

BRAF Inhibitors

Topoisomerase Inhibitors

Pyrazole Compounds

Transition Metal Complexes

162 patents: Sort by Forward Citations

1. 11497733 - Combination therapy of HSP90 inhibitors and PD-1 inhibitors for treating cancer (2022-11-15),

2. 11154538 - Combination therapy for treatment of ovarian cancer (2021-10-26),

3. 10500193 - Combination therapy of HSP90 inhibitors with platinum-containing agents (2019-12-10),

4. 9604978 - Compounds for inflammation and immune-related uses (2017-03-28),

5. 9597343 - Targeted therapeutics (2017-03-21),

6. 9539243 - Triazole compounds that modulate HSP90 activity (2017-01-10),

7. 9493427 - Compounds for inflammation and immune-related uses (2016-11-15),

8. 9439899 - Cancer therapy using a combination of HSP90 inhibitors with topoisomerase I inhibitors (2016-09-13),

9. 9402831 - Combination therapy of HSP90 inhibitors with BRAF inhibitors (2016-08-02),

10. 9206162 - Triazole compounds that modulate Hsp90 activity (2015-12-08),

11. 9205086 - Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor (2015-12-08),

12. 9175022 - Compounds for the treatment of proliferative disorders (2015-11-03),

13. 9174935 - Transition metal complexes of bis[thiohydrazide amide] compounds (2015-11-03),

14. 9156836 - Tricyclic triazole compounds that modulate HSP90 activity (2015-10-13),

15. 9156794 - Imidazole compounds that modulate HSP90 activity (2015-10-13),

Synta Pharmaceuticals Corporation is a biopharmaceutical company focused on discovering, developing, and commercializing innovative oncology medicines. With a strong commitment to improving patient outcomes, Synta Pharmaceuticals leverages its deep expertise in targeted therapies and drug discovery to advance treatments for various types of cancer. Through rigorous scientific research and collaboration with leading medical institutions, the company aims to address unmet medical needs and create value for patients, healthcare providers, and investors.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

162 Patents

#3 in Lexington, MA

#131 in Massachusetts

#2,375 in US

#4,956 in the World

Lexington, MA, United States of America

Synta Pharmaceuticals Corporation

Forward Citations = 1,723

71 inventors:

Lijun Sun (100 out of 140 patents)

Shoujun Chen (66 out of 71 patents)

Weiwen Ying (54 out of 63 patents)

4. Keizo Koya (49 out of 58 patents)

5. Mitsunori Ono (38 out of 94 patents)

Please report any incorrect information to support@idiyas.com

Loading…